Intraoperative Retinal Changes May Predict Surgical Outcomes After Epiretinal Membrane Peeling.


Journal

Translational vision science & technology
ISSN: 2164-2591
Titre abrégé: Transl Vis Sci Technol
Pays: United States
ID NLM: 101595919

Informations de publication

Date de publication:
05 02 2021
Historique:
entrez: 18 5 2021
pubmed: 19 5 2021
medline: 29 6 2021
Statut: ppublish

Résumé

To investigate whether intraoperative retinal changes during epiretinal membrane (ERM) peeling affect anatomic or functional outcomes after surgery. We measured retinal thickness using an intraoperative optical coherence tomography (iOCT) device in patients undergoing pars plana vitrectomy with membrane peeling for idiopathic ERM. Changes in intraoperative central macular thickness (iCMT) were compared with postoperative improvements in CMT and best-corrected visual acuity (VA). Twenty-seven eyes from 27 patients (mean age 68 years) underwent iOCT-assisted ERM peeling surgery. Before surgery, mean VA was logMAR 0.50 ± 0.36 (Snellen 20/63), and mean baseline CMT was 489 ± 82 µm. Mean iCMT before peeling was 477 ± 87 µm, which correlated well with preoperative CMT (P < 0.001). Mean change in iCMT was -39.6 ± 37 µm (range -116 to +77 µm). After surgery, VA improved to logMAR 0.40 ± 0.38 (Snellen 20/50) at month 1 and logMAR 0.27 ± 0.23 (Snellen 20/37) at month 3, whereas CMT decreased to 397 ± 44 µm and 396 ± 51 µm at months 1 and 3. Eyes that underwent greater amount of iCMT change (absolute value of iCMT change) were associated with greater CMT reduction at month 1 (P < 0.001) and month 3 (P = 0.010), whereas those with greater intraoperative thinning (actual iCMT change) showed a trend toward better VA outcomes at months 1 (P = 0.054) and 3 (P = 0.036). Intraoperative changes in retinal thickness may predict anatomic and visual outcomes after idiopathic ERM peeling surgery. Our study suggests that intraoperative retinal tissue response to ERM peeling surgery measured by iOCT may be a prognostic indicator for restoration of retinal architecture and for visual acuity outcomes.

Identifiants

pubmed: 34003921
pii: 2772318
doi: 10.1167/tvst.10.2.36
pmc: PMC7910632
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

36

Subventions

Organisme : NEI NIH HHS
ID : K08 EY027463
Pays : United States

Références

Retina. 2009 Nov-Dec;29(10):1457-68
pubmed: 19823107
Am J Ophthalmol. 2021 Jan;221:154-168
pubmed: 32707207
Br J Ophthalmol. 2013 Sep;97(9):1197-201
pubmed: 23832965
JAMA Ophthalmol. 2015 Oct;133(10):1124-32
pubmed: 26226623
Ophthalmology. 2011 Nov;118(11):2212-7
pubmed: 21906815
Ophthalmol Retina. 2018 Apr;2(4):263-267
pubmed: 29651467
Int Ophthalmol Clin. 2011 Fall;51(4):67-83
pubmed: 21897141
Transl Vis Sci Technol. 2019 Feb 6;8(1):18
pubmed: 30746303
Invest Ophthalmol Vis Sci. 2013 Nov 15;54(12):7595-602
pubmed: 24084089
Invest Ophthalmol Vis Sci. 2011 May 16;52(6):3153-9
pubmed: 21282565
Am J Ophthalmol. 2012 Jan;153(1):103-10.e1
pubmed: 21937015
Eye (Lond). 2011 Feb;25(2):180-4
pubmed: 21109773
Int J Ophthalmol. 2017 Dec 18;10(12):1877-1882
pubmed: 29259907
Eye (Lond). 2019 May;33(5):714-723
pubmed: 31000833
Am J Ophthalmol. 2017 Dec;184:108-114
pubmed: 29038011
Retina. 2011 Jul-Aug;31(7):1332-6
pubmed: 21273942
J Ophthalmic Vis Res. 2015 Jul-Sep;10(3):309-15
pubmed: 26730318
Ophthalmol Retina. 2019 Mar;3(3):252-257
pubmed: 31014703
Am J Ophthalmol. 2016 Sep;169:104-112
pubmed: 27345731
Br J Ophthalmol. 2014 Oct;98(10):1329-32
pubmed: 24782469
Curr Eye Res. 2012 Jan;37(1):50-4
pubmed: 21988485
Eur J Ophthalmol. 2018 May;28(3):329-332
pubmed: 29077190
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7324-30
pubmed: 26559478
Case Rep Ophthalmol. 2016 Jul 21;7(2):372-376
pubmed: 27721786
Ophthalmic Surg Lasers Imaging. 2012 Nov-Dec;43(6 Suppl):S54-60
pubmed: 23357325
Am J Ophthalmol. 2014 Nov;158(5):999-1007
pubmed: 25077834
Sci Rep. 2016 Aug 19;6:31689
pubmed: 27538478
Ophthalmology. 2018 Jul;125(7):1014-1027
pubmed: 29409662

Auteurs

Lekha K Mukkamala (LK)

Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.

Jaycob Avaylon (J)

California Northstate University, College of Medicine, Elk Grove, CA, USA.

R Joel Welch (RJ)

Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.

Amirfarbod Yazdanyar (A)

Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.

Parisa Emami-Naeini (P)

Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.

Sophia Wong (S)

Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.

Jordan Storkersen (J)

California Northstate University, College of Medicine, Elk Grove, CA, USA.

Jessica Loo (J)

Department of Biomedical Engineering, Duke University, Durham, NC, USA.

David Cunefare (D)

Department of Biomedical Engineering, Duke University, Durham, NC, USA.

Sina Farsiu (S)

Department of Biomedical Engineering, Duke University, Durham, NC, USA.

Ala Moshiri (A)

Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.

Susanna S Park (SS)

Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.

Glenn Yiu (G)

Department of Ophthalmology & Vision Science, University of California, Davis, Sacramento, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH